Sanifit's calcification drug hits goal in renal disease phase 2b

Kidney care
Sanifit is set to share detailed data on its calcification inhibitor next month. (Getty/Trish233)

A phase 2b trial of Sanifit’s SNF472 in hemodialysis patients has hit its primary endpoint, teeing the Spanish biotech up to take the calcification inhibitor forward.

Sanifit, a 2019 Fierce 15 winner, is currently gearing up to run a phase 3 trial of SNF472 in calciphylaxis, a disease characterized by the accumulation of calcium in small blood vessels that most commonly occurs in end-stage renal disease (ESRD) patients. ESRD patients on hemodialysis are prone to major, fast-progressing vascular calcification associated with cardiovascular mortality. 

The latest clinical assessment of SNF472 enrolled 274 ESRD patients and randomized them to take the calcification inhibitor or placebo for 52 weeks. By the end of the study, Sanifit had linked use of its drug to reduced coronary artery calcium volume compared to placebo, resulting in the trial hitting its primary goal. 

Sponsored by BHE

[Webinar] State of Data Analytics and Machine Learning in the Life Sciences Industry: 2020 Benchmarking Survey

Thursday, June 25, 2020 | 2:00pm ET | 11:00am PT

Join us Thursday, June 25th for a look at the current state of analytics in the life sciences industry. We will present the results from our industry survey with FiercePharma on how 100 of your peers are leveraging data analytics to respond to today’s challenges and generate timely, high value insights.

That finding appears to validate Sanifit’s belief that SNF472 can help ESRD patients by binding to the growth sites of crystals that make up the problematic calcium deposits. However, Sanifit is yet to share any numbers or information beyond the primary endpoint success, leaving scope for safety or efficacy details to undermine its case for SNF472 when it shares detailed data next month. 

The presentation of the phase 2b data will provide the most comprehensive look at the effects of the drug to date. Sanifit previously shared data from a 14-subject clinical trial that assessed the effect of SNF472 on wound healing and pain. Those endpoints reflect the potential for calciphylaxis to cause necrotic skin ulcers.

At the time of its €55.2 million ($61.4 million) series D round in June, Sanifit planned to run a phase 3 trial using the same wound healing and pain endpoints as the 14-patient study. The phase 2b results suggest Sanifit may also be able to make the case for SNF472 by focusing on coronary artery calcium volume and potentially cardiovascular outcomes. 

That thinking has informed Sanifit’s belief that SNF472 may have a future in indications including peripheral artery disease and cardiovascular disease, conditions that affect significant numbers of ESRD patients. 

Suggested Articles

The FDA granted new COVID-19 green lights to Fitbit’s emergency ventilator alternative, as well as to a second device designed by NASA engineers.

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.